NEWS

2026

  • Awarded an IPPP pilot grant from the HICCC.

  • Suyeon Kim was awarded the ACS Postdoctoral Fellowship. Congratulations, Suyeon!

  • Sungsoo Kim accepted a tenure-track Assistant Professor position at Ewha University, Korea. Congratulations, Sungsoo!

  • Awarded the DoD Breast Cancer Breakthrough Award.

  • Awarded a Melanoma Research Alliance (MRA) pilot award.

  • Awarded the Irma T. Hirschl Research Award.

2025

  • Jessica Armand successfully defended her PhD. Congratulations, Dr. Armand!

  • Sungsoo Kim received a Travel Grant to attend ASCB 2025.

  • The study led by Sungsoo Kim and Eugene Son on triple-negative breast cancer was accepted at the Journal of Clinical Investigation. Congratulations to all co-authors!

  • Kibum Kim's study on whole-genome duplication was published in Nature Communications. Congratulations to all co-authors!

  • Awarded a Melanoma Research Foundation Breakthrough Consortium (MRFBC) pilot award.

2024

  • Suyeon Kim received a postdoctoral fellowship from the National Research Foundation of Korea. Congratulations, Suyeon!

  • Sungsoo Kim received a postdoctoral fellowship from the Precision Oncology Systems Biology program at HICCC. Congratulations, Sungsoo!

2023

  • Our study on the non-canonical pathway for Rb inactivation was accepted at Nature Communications. Congratulations to Mimi Zhang and Sungsoo Kim!

  • Our study on CDK4/6 inhibitor resistance in breast cancer was accepted at Cell Reports. Congratulations to Sungsoo Kim and all co-authors!

  • Sungsoo Kim received a Scholar-in-Training Award from AACR.

  • Awarded the V Scholar Grant from the V Foundation.

  • Awarded an R01 grant from the NIH NIGMS.

  • Awarded the Research Scholar Grant (RSG) from the American Cancer Society.

2022

  • Awarded a Career Development Award from the Melanoma Research Foundation.

  • Awarded the Center for Precision Cancer Medicine Pilot Grant.

2021

  • Awarded the Velocity Award.

2020

  • Awarded a pilot grant to develop a high-throughput screening platform for COVID-19 drugs.